Ranbaxy Stability Testing System Draws FDA GMP Warning Letter
This article was originally published in The Pink Sheet Daily
An FDA analysis of isotretinoin samples following a February inspection finds “lower potencies in these batches” before their expiration dates.
You may also be interested in...
Ranbaxy may be subject to third-party supervision of its manufacturing of the antiviral ganciclovir, in return for gaining an exception for the product from FDA's Import Alert
Roche will consider requesting a re-examination of the negative decision by the Committee for Medicinal Products for Human Use.